

CI Global Health Sciences Corporate Class

Series P CAD



AS AT MARCH 31, 2024

FUND OVERVIEW

This fund invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry.

FUND DETAILS

Inception date	May 2017
CAD Total net assets (\$CAD) As at 2024-03-28	\$147.1 million
NAVPS	\$13.3842
MER (%) As at 2023-09-30	0.24
Management fee (%)	Negotiable
Asset class	Sector Equity
Currency	CAD
Minimum investment	\$500 initial/\$25 additional
Distribution frequency	Quarterly
Last distribution	\$0.2081

Risk rating¹




FUND CODES

P	90024
A	ISC 201 DSC SO* 701 LL SO 1701
E	16005
EF	15005
F	224
I	886
O	18005


*No new purchases directly into switch only funds.

PERFORMANCE²

Growth of \$10,000 (since inception date)



Calendar year performance



Average annual compound returns

YTD	1 Mo	3 Mo	6 Mo	1 Y	3 Y	5 Y	10 Y	Inception*
9.82%	1.16%	9.82%	12.80%	16.48%	3.95%	6.79%	-	6.66%

*Since inception date


DISTRIBUTION HISTORY³

Payable date	Total	Payable date	Total
2022-03-25	0.2081	2020-03-20	0.2055
2021-03-26	0.0708	2019-12-13	0.1173
2020-12-18	0.1141	2019-09-27	0.1312
2020-09-25	0.1130	2019-06-21	0.1228
2020-06-26	0.0840	2019-03-22	0.1957


CI PREFERRED PRICING⁴

Investment amount	Combined fee reduction
\$100,000 - \$500,000	0.03%
\$500,000 - \$1,000,000	0.06%
\$1,000,000 - \$2,500,000	0.12%
\$2,500,000 - \$5,000,000	0.20%
\$5,000,000 and above	0.32%

MANAGEMENT TEAM



Greg Quickmire



Peter Hofstra

AS AT MARCH 31, 2024

PORTFOLIO ALLOCATIONS⁵

Asset allocation	(%)	Sector allocation	(%)	Geographic allocation	(%)
US Equity	79.07	Healthcare	92.77	United States	81.02
International Equity	18.76	Exchange Traded Fund	3.02	United Kingdom	7.93
Cash and Equivalents	2.12	Cash and Cash Equivalent	2.12	Denmark	7.76
Other	0.05	Consumer Services	2.04	Germany	3.13
		Other	0.05	Canada	0.08
				Other	0.05
				Switzerland	0.03

TOP HOLDINGS

	Sector	(%)
1. Eli Lilly and Co	Drugs	10.16%
2. UnitedHealth Group Inc	Healthcare Services	9.63%
3. Novo Nordisk A/S CI B	Drugs	7.72%
4. Humana Inc	Healthcare Services	7.01%
5. Merck & Co Inc	Drugs	5.31%
6. AstraZeneca PLC	Drugs	4.81%
7. AbbVie Inc	Drugs	4.19%
8. Zoetis Inc CI A	Drugs	3.92%
9. Anthem Inc	Healthcare Services	3.14%
10. Siemens Healthineers AG	Healthcare Equipment	3.13%
11. Boston Scientific Corp	Healthcare Equipment	3.10%
12. Gsk Plc	Drugs	3.10%
13. Thermo Fisher Scientific Inc	Healthcare Equipment	3.02%
14. SPDR S&P Biotech ETF (XBI)	Exchange Traded Fund	3.02%
15. Stryker Corp	Healthcare Equipment	3.01%

Over 35,000 financial advisors have chosen CI Global Asset Management as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. [Learn more at ci.com.](#)

¹ The risk level of a fund has been determined in accordance with a standardized risk classification methodology in National Instrument 81-102, that is based on the fund's historical volatility as measured by the 10-year standard deviation of the fund's returns. Where a fund has offered securities to the public for less than 10 years, the standardized methodology requires that the standard deviation of a reference mutual fund or index that reasonably approximates the fund's standard deviation be used to determine the fund's risk rating. Please note that historical performance may not be indicative of future returns and a fund's historical volatility may not be indicative of future volatility.

² Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Please read the prospectus before investing. The indicated rates of return are the historical annual compounded total returns net of fees and expenses payable by the fund (except for figures of one year or less, which are simple total returns) including changes in security value and reinvestment of all dividends/distributions and do not take into account sales, redemption, distribution or optional charges or income taxes payable by any securityholder that would have reduced returns. Mutual funds are not guaranteed, their values change frequently, and past performance may not be repeated.

³ Please refer to the fund's simplified prospectus for distribution information.

⁴ CI Preferred Pricing fee reductions apply to management and administration fees and start at \$100,000.

⁵ Portfolio allocations will fluctuate over the life of the mutual fund as the portfolio holdings and market value of each security changes. The portfolio manager(s) may change the portfolio allocations in some or all of the sectors.

The contents are not to be used or construed as investment advice or as an endorsement or recommendation of any entity of security discussed.

Certain statements contained in this communication are based in whole or in part on information provided by third parties and CI has taken reasonable steps to ensure their accuracy.

The rates of return are used only to illustrate the effects of the compound growth rate and are not intended to reflect future values or returns on investment in an investment fund.

The "Growth of \$10,000 invested" chart shows the final value of a hypothetical \$10,000 investment in securities in this class/series of the fund as at the end of the investment period indicated and is not intended to reflect future values or returns on investment in such securities.

Management Expense Ratio ("MER") represents the trailing 12-month management expense ratio, which reflects the cost of running the fund, inclusive of applicable taxes including HST, GST and QST (excluding commissions and other portfolio transaction costs) as a percentage of daily average net asset value the period, including the fund's proportionate share of any underlying fund(s) expenses, if applicable. The MER is reported in each fund's Management Report of Fund Performance ("MRFP"). MRFPs can be found within the Documents tab on ci.com.

CI Global Asset Management is a registered business name of CI Investments Inc.

©CI Investments Inc. 2024. All rights reserved.

Published April 2024